Xelstrym

Xelstrym is the dextroamphetamine transdermal system, approved in the United States in 2022. The active drug is plain dextroamphetamine, the same molecule as in oral immediate-release products and the same molecule lisdexamfetamine releases; everything distinctive about it is the route.

Transdermal delivery changes three practical things. It bypasses the gut, which matters for people who cannot reliably swallow capsules, who have had bariatric surgery, or whose absorption is erratic. It produces a gradual rise rather than an oral peak. And, unusually among long-acting stimulants, it can be stopped: removing the patch begins the offset, so a dose does not have to be endured for its full duration if the evening matters. The intended wear time is about nine hours, and the effect continues for a period after removal rather than ceasing at once ^[2].

Efficacy was established in a pivotal phase 2 study in children and adolescents, with the improvement in ADHD symptoms consistent with what oral dextroamphetamine achieves ^[1]. A later critical review examined its place against the alternatives in both adults and children and treated it as a delivery option rather than a therapeutic advance ^[2].

The costs are the ones patches bring. Application-site reactions are the most common complaint, and the transdermal ADHD stimulant that preceded it established that skin depigmentation at the application site is a genuine if uncommon risk of this route. Everything after absorption is amphetamine, so the class risks apply unchanged: raised cardiovascular risk with cumulative exposure ^[3], and a psychosis risk roughly double that of methylphenidate ^[4].

Two categories, and they should be read separately.

The route contributes application-site reactions, which are the most frequent complaint and are usually mild redness or itching. The more serious route-specific concern is depigmentation of the skin at the application site; this was established with the methylphenidate transdermal system that preceded it, and it is a property of delivering a stimulant through skin rather than of any one molecule. Rotating sites is the standard mitigation. A patch also has to be disposed of carefully, since a used one still contains drug.

The drug contributes everything the amphetamine class contributes, unchanged. Cumulative stimulant exposure raises cardiovascular risk over years, mainly through hypertension and arterial disease ^[3]. New-onset psychosis is roughly twice as likely on an amphetamine as on methylphenidate, at about one in 660 patients starting treatment ^[4]. Appetite suppression, weight effects and disrupted sleep persist as long as treatment does, and long-term follow-up of stimulant-treated ADHD found measurable adult height suppression in those medicated consistently through growth ^[6][5].

It is a controlled substance with the abuse liability of dextroamphetamine. This entry is educational and is not medical advice.

The idea of a stimulant patch for ADHD is older than this product. A methylphenidate transdermal system reached the market in 2006 and established both the rationale, which is a smooth profile with a removable dose, and the characteristic drawback, which is skin reactions and occasional depigmentation at the application site.

The amphetamine equivalent took another fifteen years. Xelstrym was approved in the United States in 2022 as the first dextroamphetamine transdermal system, on the strength of a pivotal phase 2 study in children and adolescents that showed symptom improvement consistent with oral dextroamphetamine ^[1]. A critical review in 2024 assessed its place against existing options across adult and paediatric use ^[2].

Its arrival completes a long pattern in this category, where the molecules have barely changed since the mid-twentieth century and essentially all the development effort has gone into delivery: extended-release beads, osmotic pumps, prodrugs cleaved in blood or gut, and now a second patch.

Xelstrym is too new to have much of a reputation and is mostly discussed as a niche solution rather than a mainstream choice, which is a fair reading of it. Clinically the interest is concentrated in specific situations: patients who cannot reliably swallow capsules, children who refuse them, people with bariatric surgery or erratic gastrointestinal absorption, and anyone who needs the option to end a dose early rather than wait out a twelve-hour oral product.

That last property is the one users tend to find most valuable and is genuinely uncommon in this category. Every other long-acting stimulant commits you to its duration once swallowed.

The scepticism is about proportion rather than merit. It is an old drug in a new wrapper, priced as a new product, and it adds a category of adverse effect that oral formulations do not have. The comparison people most want, patch against an equivalent oral extended-release amphetamine on tolerability and adherence, has not been run in a way that would settle it, and the 2024 review treats it as an option among several rather than an advance over them ^[2].